Teva brings another action against Mylan

Generics/News | Posted 03/12/2010 post-comment0 Post your comment

In October 2009, Teva Pharmaceutical Industries filed a lawsuit against Mylan for infringement of multiple patents, with respect to patents on its glatiramer acetate drug–Copaxone. The patents cover pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.

picture10

The latest action by Teva, brought in September 2010, concerns infringement of four patents related to the characterisation of Copaxone. The latest of these patents expires in February 2020.

Earlier in September 2010, Teva won a ruling in its battle to protect Copaxone. A court in the US denied a motion filed by Sandoz (the generics’ branch of Novartis) and Momenta Pharmaceuticals seeking to invalidate patents.

Copaxone multiple sclerosis treatment was developed by generics company Teva itself and is proving very lucrative. The ability for Teva to ward off generic competitors to Copaxone is one of the top concerns for investors in the Israel-based company.

Related article

FDA rejects second citizen petition for Teva’s glatiramer acetate drug

Source: Teva Press Release. Teva Files Complaint against Mylan for Infringement of Four Copaxone-Related Patents. 21 September 2010.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010